Study to Assess the Long-term Safety, Tolerability, and Efficacy of AMG 827 in Subjects With Psoriasis
| Status: | Terminated |
|---|---|
| Conditions: | Psoriasis |
| Therapuetic Areas: | Dermatology / Plastic Surgery |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 10/14/2017 |
| Start Date: | April 2010 |
| End Date: | September 2015 |
A Long-term Assessment of the Safety and Efficacy of AMG 827 Subcutaneous Treatment in Subjects With Psoriasis
This study is an open-label extension of study 20090062 to evaluate extended subcutaneous
dosing of AMG 827 for up to 362 weeks.
dosing of AMG 827 for up to 362 weeks.
Inclusion Criteria:
- Subject was randomized into Study 20090062 and completed the week 16 evaluation.
Exclusion Criteria:
- Subject had any Serious Adverse Event (SAE) reported during Study 20090062 that was
considered possibly related to IP.
- Subject experienced an adverse event in Study 20090062 that, in the opinion of the
investigator, could cause extension of treatment to be detrimental to the subject.
We found this trial at
7
sites
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials